Press Releases

 
Press Releases
  Date Title View
11-20-12
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that C. Randal Mills, Ph.D., President a...
11-05-12
Biosurgery sales up 6-fold over previous year - Osiris regains worldwide rights to Prochymal COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in ...
10-29-12
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the third quarter ended September 30, 2012, on Monday, November 5, 2012. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief ...
10-22-12
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today it has promoted Lode Debrabandere, Ph.D. to the role of Chief Operating Officer (COO) reporting directly to Chief Executive Officer, C. Randal Mills, Ph.D. Dr. Debrabandere has been with Osiris since 2006 in various...
09-28-12
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today that it has been notified by Swissmedic, the Swiss agency responsible for the evaluation of drugs, that Prochymal® (remestemcel-L) will be evaluated under its Rapid Authorization Procedures. This designation, a...
09-28-12
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced the conclusion of its collaboration with Genzyme, a Sanofi company. As the Collaboration Agreement is now ended, all rights to Prochymal® and ChondrogenTM worldwide revert back to Osiris. Osiris is now free to ...
09-20-12
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today the passing of one of its Board Members, Gregory H. Barnhill. Mr. Barnhill has served on Osiris' Board of Directors since the company went public in August of 2006 and was a member of the Audit, Nominating and Compe...
09-19-12
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that C. Randal Mills, Ph.D., President a...
07-30-12
Biosurgery sales rise 43% over prior quarter, Prochymal® becomes first approved stem cell drug and company ends the first half with $40 million in cash and no debt COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company ...
07-23-12
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the second quarter ended June 30, 2012, on Monday, July 30, 2012. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financi...
1
NextLast
= add release to Briefcase